Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Circulating MicroRNA Profiles as Potential Biomarkers for differentiated thyroid cancer recurrence

ABSTRACT: Circulating MicroRNA Profiles as Potential Biomarkers for differentiated thyroid cancer recurrence

PROVIDER: PRJNA724877 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14319800.fastq.gz	Fastqsanger.gz
	SRR14319801.fastq.gz	Fastqsanger.gz
	SRR14319802.fastq.gz	Fastqsanger.gz
	SRR14319803.fastq.gz	Fastqsanger.gz
	SRR14319804.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

Circulating MicroRNA Profiles as Potential Biomarkers for differentiated thyroid cancer recurrence

Project description:This study sought to identify the profile of circulating miRNAs and its response to human recombinant TSH in thyroid cancer patients with recurrent disease

2021-04-25 | GSE173248 | GEO

Circulating microRNAs predict biochemical recurrence in prostate cancer patients

Project description:Comparison of circulating miRNA levels in patients who experienced rapid biochemical recurrence or no recurrence following radical prostatectomy qRT-PCR miRNA expression profiling of patient serum

2013-05-22 | E-GEOD-47125 | biostudies-arrayexpress

PIAS2b dsRNAi repression kills by mitotic catastrophe anaplastic thyroid and non-thyroid carcinomas, but not normal thyroid or differentiated carcinomas

Project description:The E3 SUMO ligase PIAS2 is expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anaplastic thyroid carcinomas (ATC), an undifferentiated cancer with very high mortality. Double-stranded RNA–directed RNA interference (dsRNAi) targeting the PIAS2 isoform beta (PIAS2b) inhibits growth of ATC cell lines and patient primary cultures in vitro and orthotopic patient-derived xenografts (oPDX) in vivo, but not of thyroid cell lines or non-anaplastic primary thyroid cultures (differentiated carcinoma, benign lesions, or normal). PIAS2b-dsRNAi also has an anti-cancer effect on other anaplastic human cancers (pancreas, lung, and gastric). Mechanistically, PIAS2b is required for proper mitotic spindle and centrosome assembly, and it is a dosage-sensitive protein in ATC. Strikingly, PIAS2b-dsRNAi induces mitotic catastrophe at prophase. High-throughput proteomics revealed the proteasome (PSMC5) and spindle cytoskeleton as direct targets of PIAS2b SUMOylation at mitotic initiation. PIAS2b-dsRNAi is a promising therapy for ATC and other aggressive anaplastic cancers.

2024-04-08 | PXD044110 | Pride

Circulating microRNAs predict biochemical recurrence in prostate cancer patients

Project description:Comparison of circulating miRNA levels in patients who experienced rapid biochemical recurrence or no recurrence following radical prostatectomy

2013-05-22 | GSE47125 | GEO

Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy

Project description:This SuperSeries is composed of the following subset Series: GSE26022: [Gene Expression Training Set] Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy GSE26242: [Gene Expression Validation Set] Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy GSE26245: [miRNA Training Set] Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy GSE26247: [miRNA Validation Set] Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy Refer to individual Series

2011-06-01 | E-GEOD-26367 | biostudies-arrayexpress

Proteomic analysis of radioiodine-refractory differentiated thyroid cancer

Project description:Radioiodine refractory differentiated thyroid cancer (RR-DTC) is the main factor affecting the overall survival rate of thyroid cancer clinically. In order to investigate its underlying molecular mechanism of pathogenesis with the hope to explore novel therapeutic targets for clinical treatment, we performed a comparative proteomic analysis in tumor tissue of patients with RR-DTC and papillary thyroid cancer.

2022-11-05 | PXD037968 |

Murine: papillary thyroid cancer vs. poorly differentiated thyroid cancer

Project description:Mice with thyroid-specific expression of oncogenic BRAF (Tg-Braf) develop papillary thyroid cancers (PTC) that are locally invasive and have well-defined foci of poorly differentiated thyroid carcinoma (PDTC). To investigate the PTC-PDTC progression, we performed a microarray analysis using RNA from paired samples of PDTC and PTC collected from the same animals by laser capture microdissection. Analysis of 8 paired samples revealed a profound deregulation of genes involved in cell adhesion and intracellular junctions, with changes consistent with an epithelial-mesenchymal transition (EMT). This was confirmed by IHC, as vimentin expression was increased and E-cadherin lost in PDTC compared to adjacent PTC. Moreover, PDTC stained positively for phospho-Smad2, suggesting a role for transforming growth factor-beta (TGFbeta) in mediating this process. Accordingly, TGFbeta induced EMT in primary cultures of thyroid cells from Tg-Braf mice, whereas wild-type thyroid cells retained their epithelial features. TGFbeta-induced Smad2 phosphorylation, transcriptional activity and induction of EMT required MAPK pathway activation in Tg-Braf thyrocytes. Hence, tumor initiation by oncogenic BRAF renders thyroid cells susceptible to TGFbeta-induced EMT, through a MAPK-dependent process. Comparing the transcription profiles of 8 pairs of murine poorly differentiated thyroid cancer and papillary thyroid cancer collected from the same animals by laser capture microdissection. Co-hybridizations were done in triplicate with a single dye flip.

2011-03-22 | E-GEOD-27668 | biostudies-arrayexpress

Biomarkers of lung metastasis in differentiated thyroid cancer based on proteomic analysis

Project description:The high incidence of differentiated thyroid carcinoma (DTC) leads to a significant increase in the number of patients with lung metastatic DTC (LMDTC), making this population a key focus and challenge in clinical practice, so there is an urgent need to find effective methods to guide risk stratification and predict the risk of metastasis in this group of patients. This study is significant in its theoretical and technical advancement as it based on primary lesion 4D label-free proteomic analysis, combined with PRM validation, to identify potential biomarkers (8 key DEPs) for predicting DTC lung metastasis.

2024-01-10 | PXD048443 |

Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas

Project description:Poorly differentiated thyroid carcinomas (PDTC) represent a heterogeneous, aggressive entity, presenting features that suggest a progression from well-differentiated carcinomas. To elucidate the mechanisms underlying such progression and identify novel therapeutical targets, we assessed the genome-wide expression in normal thyroid tissues, well-differentiated thyroid carcinomas and PDTC.

2013-12-10 | GSE53157 | GEO

EV-miRNAs as biomarkers of breast cancer recurrence

Project description:EV-miRNAs as biomarkers of breast cancer recurrence

| PRJNA992498 | ENA